Decoy Therapeutics (DCOY)
NASDAQ:DCOY
Want to see DCOY full AI Analyst Report?
DCOY Stock Chart & Stats
$5.81
-$0.06(-3.48%)
At close: 4:00 PM EST
$5.81
-$0.06(-3.48%)
Day’s Range― - ―
52-Week Range$4.32 - $416.05
Previous CloseN/A
VolumeN/A
Average Volume (3M)356.88K
Market Cap
$3.25M
Enterprise Value-$4.69M
Total Cash (Recent Filing)$7.82M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.84
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding531,968
10 Day Avg. Volume434,140
30 Day Avg. Volume356,875
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.64
Price to Sales (P/S)0.00
P/FCF Ratio-0.78
Enterprise Value/Market Cap-1.45
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit0.55
Enterprise Value/Ebitda0.36
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / No DebtZero reported debt gives the company structural financial flexibility, lowering interest burden and preserving capacity to raise targeted capital for R&D. Over 2–6 months this reduces solvency risk and allows management to prioritize program funding rather than debt service.
Regained Nasdaq Compliance After Reverse SplitRestoring compliance via the reverse split removed immediate delisting threat and preserves the company’s public listing, which is structurally important for access to equity capital and partnering. This materially reduces short-term existential risk to ongoing R&D programs.
Smaller Losses Vs. 2022The marked reduction in annual losses versus 2022 indicates improved cost control or program prioritization, reflecting a more sustainable burn profile. As a durable trend, this supports extending runway and demonstrating management discipline in resource allocation.
Bears Say
Pre-revenue Business ModelBeing pre-revenue leaves the firm dependent on external financing rather than operating cash flow. Over the medium term this limits visibility into commercial viability, increases investor dependence on development milestones, and raises execution risk for long-term sustainability.
Sustained Cash Burn And Negative FCFPersistent negative operating and free cash flow means the company is consuming cash to fund operations and R&D. This durable cash outflow profile necessitates recurring external financing, increasing dilution risk and constraining strategic optionality over the next several quarters.
Eroding Shareholders' EquityThe steady decline in equity reflects cumulative losses and capital depletion, weakening the company’s financial cushion. Over 2–6 months this reduces balance-sheet resilience, heightens dependence on new capital, and increases vulnerability to adverse funding conditions.
Decoy Therapeutics News
DCOY FAQ
What was Decoy Therapeutics’s price range in the past 12 months?
Decoy Therapeutics lowest stock price was $4.32 and its highest was $416.05 in the past 12 months.
What is Decoy Therapeutics’s market cap?
Decoy Therapeutics’s market cap is $3.25M.
When is Decoy Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Decoy Therapeutics’s earnings last quarter?
Currently, no data Available
Is Decoy Therapeutics overvalued?
According to Wall Street analysts Decoy Therapeutics’s price is currently Overvalued.
Does Decoy Therapeutics pay dividends?
Decoy Therapeutics does not currently pay dividends.
What is Decoy Therapeutics’s EPS estimate?
Decoy Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Decoy Therapeutics have?
Decoy Therapeutics has 531,968 shares outstanding.
What happened to Decoy Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Decoy Therapeutics?
Currently, no hedge funds are holding shares in DCOY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Decoy Therapeutics
Based in Cambridge, Massachusetts, Decoy Therapeutics Inc. is an early-stage biotechnology firm dedicated to tackling critical unmet medical needs. The company employs cutting-edge machine learning and AI technologies, alongside accelerated synthesis methods, to swiftly design, engineer, and manufacture innovative peptide conjugate drug candidates.
Technical Analysis
Biodexa Pharmaceuticals
―
Q/C Technologies
―
Scinai Immunotherapeutics
―
Oragenics
―
Onconetix
―
Ownership Overview
Options Prices
Currently, No data available
---